Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,597,885 shares of the biopharmaceutical company’s stock after selling 283,937 shares during the quarter. Thrivent Financial for Lutherans owned about 0.13% of Gilead Sciences worth $132,566,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. ST Germain D J Co. Inc. boosted its position in Gilead Sciences by 15.2% during the fourth quarter. ST Germain D J Co. Inc. now owns 4,246 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 560 shares during the last quarter. Heritage Wealth Management LLC boosted its holdings in Gilead Sciences by 54.6% in the 4th quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 130 shares during the last quarter. SJS Investment Consulting Inc. boosted its holdings in Gilead Sciences by 187.9% in the 1st quarter. SJS Investment Consulting Inc. now owns 403 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 263 shares during the last quarter. Sanctuary Wealth Management L.L.C. acquired a new position in Gilead Sciences in the 4th quarter valued at about $33,000. Finally, Venturi Wealth Management LLC acquired a new position in Gilead Sciences in the 1st quarter valued at about $36,000. 82.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the chief financial officer now owns 107,587 shares in the company, valued at approximately $8,606,960. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on GILD. BMO Capital Markets decreased their target price on shares of Gilead Sciences from $100.00 to $95.00 in a report on Tuesday, July 18th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $83.00 to $84.00 and gave the company a “sector perform” rating in a report on Friday, August 4th. Bank of America upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $88.00 to $95.00 in a report on Friday, September 8th. Morgan Stanley upped their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a research note on Friday, August 4th. Finally, Barclays cut their target price on shares of Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.05.

Gilead Sciences Stock Down 0.3 %

Shares of NASDAQ:GILD opened at $76.80 on Wednesday. The stock has a market cap of $95.69 billion, a P/E ratio of 17.66, a P/E/G ratio of 0.83 and a beta of 0.37. The firm has a fifty day moving average price of $77.23 and a 200 day moving average price of $78.86. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.02 and a quick ratio of 0.91. Gilead Sciences, Inc. has a 1-year low of $61.44 and a 1-year high of $89.74.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.30). The business had revenue of $6.60 billion for the quarter, compared to analyst estimates of $6.45 billion. Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.63 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.97%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.